Abbott Laboratories (ABT) is a publicly traded Healthcare sector company. As of November 18, 2026, ABT trades at $104.44 with a market cap of $186.10B and a P/E ratio of 31.73. ABT moved -2.93% today. Year to date, ABT is -17.21%; over the trailing twelve months it is -19.49%. Its 52-week range spans $81.97 to $139.06. Analyst consensus is strong buy with an average price target of $122.07. Rallies surfaces ABT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for ABT, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $104.44 |
| Market Cap | $186.10B |
| P/E Ratio | 31.73 |
| EPS | $3.10 |
| Dividend Yield | 0.63% |
| 52-Week High | $139.06 |
| 52-Week Low | $81.97 |
| Volume | 4.32M |
| Avg Volume | 0 |
| Revenue (TTM) | $46.59B |
| Net Income | $5.42B |
| Gross Margin | 56.61% |
18 analysts cover ABT: 0 strong buy, 16 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $122.07.